The Effectiveness of Raloxifene-Loaded Liposomes and Cochleates in Breast Cancer Therapy.
AAPS PharmSciTech
; 17(4): 968-77, 2016 Aug.
Article
en En
| MEDLINE
| ID: mdl-26729527
Liposome (spherical vesicles) and cochleate (multilayer crystalline, spiral structure) formulations containing raloxifene have been developed having dimethyl-ß-cyclodextrin (DM-ß-CD) or sodium taurocholate (NaTC). Raloxifene was approved initially for the treatment of osteoporosis but it is also effective on breast tissue and endometrial cells. Raloxifene inhibits matrix metalloproteinase-2 (MMP-2) enzyme, which is known to be responsible for tumor invasion and the initiation of angiogenesis during the tumor growth. Therefore, raloxifene was selected as a model drug. A series of raloxifene-loaded liposome and cochleate formulations were prepared. In vitro release studies and in vivo tests were performed. Breast cancer cell lines (MCF-7) were also used to find the most effective formulation. Highest antitumor activity was observed, and MMP-2 enzyme was also found to be inhibited with raloxifene-loaded cochleates containing DM-ß-CD. These developed formulations can be helpful for further treatment alternatives and new strategies for cancer therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ácido Taurocólico
/
Neoplasias de la Mama
/
Clorhidrato de Raloxifeno
/
Beta-Ciclodextrinas
/
Liposomas
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
AAPS PharmSciTech
Asunto de la revista:
FARMACOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Turquía
Pais de publicación:
Estados Unidos